These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16025425)

  • 1. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment.
    Kiefer F; Jahn H; Wiedemann K
    Pharmacopsychiatry; 2005 Jul; 38(4):184-6. PubMed ID: 16025425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
    Kiefer F; Jahn H; Otte C; Demiralay C; Wolf K; Wiedemann K
    J Psychiatr Res; 2005 Sep; 39(5):545-51. PubMed ID: 15992564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
    Kiefer F; Jahn H; Otte C; Naber D; Wiedemann K
    Biol Psychiatry; 2006 Jul; 60(1):74-6. PubMed ID: 16483549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
    Rösner S; Leucht S; Lehert P; Soyka M
    J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
    Snyder JL; Bowers TG
    Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers.
    Schmidt LG; Smolka MN
    Alcohol Alcohol; 2007; 42(3):241-6. PubMed ID: 17526634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid antagonists for the treatment of alcohol dependence.
    Yancey JR; Lumbad J
    Am Fam Physician; 2011 Nov; 84(9):990-2. PubMed ID: 22046937
    [No Abstract]   [Full Text] [Related]  

  • 8. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
    O'Malley SS; Krishnan-Sarin S; Farren C; Sinha R; Kreek MJ
    Psychopharmacology (Berl); 2002 Feb; 160(1):19-29. PubMed ID: 11862370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acamprosate and naltrexone: similar efficacy for relapse].
    Saitz R
    Rev Med Suisse; 2014 Dec; 10(455):2437. PubMed ID: 25752019
    [No Abstract]   [Full Text] [Related]  

  • 10. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
    Buri C; Moggi F; Giovanoli A; Strik W
    Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
    Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
    Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic approaches to the management of alcoholism.
    Anton RF
    J Clin Psychiatry; 2001; 62 Suppl 20():11-7. PubMed ID: 11584870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
    Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
    Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
    Spanagel R; Zieglgänsberger W
    Trends Pharmacol Sci; 1997 Feb; 18(2):54-9. PubMed ID: 9090311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
    Kiefer F; Helwig H; Tarnaske T; Otte C; Jahn H; Wiedemann K
    Eur Addict Res; 2005; 11(2):83-91. PubMed ID: 15785069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
    Kiefer F; Jiménez-Arriero MA; Klein O; Diehl A; Rubio G
    Addict Biol; 2008 Mar; 13(1):124-9. PubMed ID: 17573782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
    Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
    Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone: new preparation. Transient preventive efficacy on alcoholic relapse.
    Prescrire Int; 1999 Feb; 8(39):9-11. PubMed ID: 10557566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drugs against alcohol abuse].
    Mørland J
    Tidsskr Nor Laegeforen; 2006 Dec; 126(24):3268-9. PubMed ID: 17170774
    [No Abstract]   [Full Text] [Related]  

  • 20. [Neurobiological mechanisms and pharmacological treatment options for alcohol craving].
    Hillemacher T; Kornhuber J; Bleich S
    Fortschr Neurol Psychiatr; 2007 Jan; 75(1):26-32. PubMed ID: 17031777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.